Seminars in Oncology
Volume 36 , Pages S1-S5 , April 2009

Introduction: Targeting Different Pathways to Prevent Tumor Cell Development

  • Hagop M. Kantarjian

      Affiliations

    • Corresponding Author InformationAddress correspondence to Hagop M. Kantarjian, MD, Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030

References 

  1. Jehn U, Bartl R, Dietzfelbinger H, Haferlach T, Heinemann V. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia. 2004;18:1476–1481
  2. Zhou GB, Zhang J, Wang ZY, Chen SJ, Chen Z. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Philos Trans R Soc Lond B Biol Sci. 2007;362:959–971
  3. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998;339:1341–1348
  4. Slack JL, Gallagher RE. The molecular biology of acute promyelocytic leukemia. Cancer Treat Res. 1999;99:75–124
  5. Raelson JV, Nervi C, Rosenauer A, Benedetti L, Monczak Y, Pearson M, et al. The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood. 1996;88:2826–2832
  6. Nason-Burchenal K, Takle G, Pace U, Flynn S, Allopenna J, Martin P, et al. Targeting the PML/RAR alpha translocation product triggers apoptosis in promyelocytic leukemia cells. Oncogene. 1998;17:1759–1768
  7. Issa JP, Baylin SB. Epigenetics and human disease. Nat Med. 1996;2:281–282
  8. Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006;66:6361–6369
  9. Lengauer C, Issa JP. The role of epigenetics in cancer (DNA Methylation, Imprinting and the Epigenetics of Cancer—An American Association for Cancer Research Special Conference). Las Croabas, Puerto Rico, 12-16 December 1997 Mol Med Today. 1998;4:102–103
  10. Zelent A, Waxman S, Carducci M, Wright J, Zweibel J, Gore SD. State of the translational science: summary of Baltimore workshop on gene re-expression as a therapeutic target in cancer January 2003. Clin Cancer Res. 2004;10:4622–4629
  11. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109:52–57
  12. Kantarjian HM, O'Brien S, Huang X, Garcia-Manero G, Ravandi F, Cortes J, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer. 2007;109:1133–1137
  13. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24:3895–3903
  14. Goldman JM, Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1084–1086
  15. Druker BJ. Circumventing resistance to kinase-inhibitor therapy. N Engl J Med. 2006;354:2594–2596
  16. Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107:3469–3473
  17. Fenaux P, Mufti GJ, Santini V, Finelli C, Giagounidis A, Schoch C, et al. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): results of the AZA-001 phase III study [abstr 817]. Blood. 2007;110:250a
  18. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106:1569–1580
  19. Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004;103:4396–4407
  20. US Food and Drug Administration Center for Drug Evaluation and Research. Rituximab- Product Approval Information—Licensing Action. http://www.fda.gov/cder/biologics/products/ritugen112697.htmaccessed November 7, 2008
  21. US Food and Drug Administration Center for Drug Evaluation and Research. Drug Approval Package: Mylotarg (gemtuzumab ozogamicin) Injection. http://www.fda.gov/Cder/foi/nda/2000/21174_Mylotorg.htmaccessed November 7, 2008
  22. US Food and Drug Administration Center for Drug Evaluation and Research. Erbitux (cetuximab). http://www.fda.gov/cder/drug/infopage/erbitux/default.htmaccessed November 14, 2008
  23. US Food and Drug Administration Center for Drug Evaluation and Research OoODPO. FDA approves vectibix (panitumumab) to treat metastatic colorectal carcinoma. http://www.fda.gov/cder/Offices/OODP/whatsnew/panitumumab.htmaccessed November 14, 2008
  24. Mamounas EP. Present state and future prospects: a review of cooperative groups' adjuvant and neoadjuvant trials in breast cancer. Clin Breast Cancer. 2001;2(Suppl 1):S20–S30
  25. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  26. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–134
  27. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–1684
  28. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1672
  29. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat. 2005;94(Suppl 1):S5
  30. Joensuu EH, Kellokumpu-Lehtinen EA, Bono J, Alanko VJ, Kataja CE, Asola NE, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354:809–820

 STATEMENT OF CONFLICT OF INTEREST: Dr Kantarjian has received research grants from Cephalon Oncology.

PII: S0093-7754(09)00031-1

doi: 10.1053/j.seminoncol.2009.02.003

Seminars in Oncology
Volume 36 , Pages S1-S5 , April 2009

Article Tools

* Image Usage & Resolution